Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer
Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how many pathological complete responses are
achieved in patients treated with taxotere® (T) followed by Myocet® (M)and Cyclophosphamide
(MC) first line treatment in HER2 negative brest cancer patients.